# A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

> **NCT04854434** · PHASE2 · TERMINATED · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Pembrolizumab
- **DRUG:** Trifluridine
- **DRUG:** Tipiracil

## Key facts

- **NCT ID:** NCT04854434
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-29
- **Primary completion:** 2022-06-24
- **Final completion:** 2022-06-24
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854434, "A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04854434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*